









Markets
/
Stocks
/
nasdaq-tngx
/

Tango Therapeutics Inc

TNGX

12.510USD

+0.560+4.69%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.40BMarket Cap

LossP/E TTM



Tango Therapeutics Inc

12.510

+0.560+4.69%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tango Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Tango Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.38.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tango Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

11 / 392

Overall Ranking

91 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Tango Therapeutics Inc Highlights

StrengthsRisks

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 69.22% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 42.07M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 42.07M.

Undervalued

The company’s latest PE is -13.74, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 133.35M shares, decreasing 2.92% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 991.96K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.25.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

13.375

Target Price

+8.56%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Tango Therapeutics Inc is 8.25, ranking 52 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 53.81M, representing a year-over-year increase of 363.61%, while its net profit experienced a year-over-year increase of 154.46%.

Score

Industry at a Glance

Previous score

8.25

Change



Financials

8.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.33

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Tango Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Tango Therapeutics Inc is 6.19, ranking 316 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.74, which is -93.35% below the recent high of -0.91 and -4.00% above the recent low of -14.29.

Score

Industry at a Glance

Previous score

6.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Tango Therapeutics Inc is 8.80, ranking 48 out of 392 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 15.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

13.375

Target Price

+8.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Tango Therapeutics Inc

TNGX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Tango Therapeutics Inc is 9.19, ranking 31 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.98 and the support level at 10.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.91

Change

0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.089

Neutral

RSI(14)

59.688

Neutral

STOCH(KDJ)(9,3,3)

62.597

Neutral

ATR(14)

0.810

Low Volatility

CCI(14)

105.554

Buy

Williams %R

38.618

Buy

TRIX(12,20)

0.818

Sell

StochRSI(14)

67.664

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

12.254

Buy

MA10

11.926

Buy

MA20

11.914

Buy

MA50

10.428

Buy

MA100

9.264

Buy

MA200

7.033

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Tango Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 99.08%, representing a quarter-over-quarter increase of 4.54%. The largest institutional shareholder is The Vanguard, holding a total of 6.74M shares, representing 5.01% of shares outstanding, with 39.66% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Farallon Capital Management, L.L.C.

10.76M

+17.47%

EcoR1 Capital, LLC

10.63M

Boxer Capital Management, LLC

9.77M

TCG Crossover Management, LLC

8.54M

-20.49%

Third Rock Ventures, LLC

7.87M

-42.02%

The Vanguard Group, Inc.

Star Investors

5.05M

+25.46%

Woodline Partners LP

6.03M

+0.00%

Invus Public Equities Advisors, LLC

5.88M

+74.84%

Nextech Invest, Ltd.

5.53M

BlackRock Institutional Trust Company, N.A.

5.11M

+3.24%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tango Therapeutics Inc is 4.22, ranking 98 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.76. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.